Management of Sickle Cell Disease Complications Beyond Acute Chest Syndrome

References

• Fernandes Q. Therapeutic strategies in sickle cell anemia: the past present and future. Life Sci. 2017;178:100–108. doi:10.1016/j.lfs.2017.03.025
   Web of Science ®Google Scholar
• Vekilov PG. Sickle-cell haemoglobin polymerization: is it the primary pathogenic event of sickle-cell anaemia? Br J Haematol. 2007;139(2):173–184. doi:10.1111/j.1365-2141.2007.06794.x
   PubMed Web of Science ®Google Scholar
• Moerdler S, Manwani D. New insights into the pathophysiology and development of novel therapies for sickle cell disease. Hematology Am Soc Hematol Educ Program. 2018;2018(1):493–506. doi:10.1182/asheducation-2018.1.493
   Web of Science ®Google Scholar
• Piccin A, Murphy C, Eakins E, et al. Insight into the complex pathophysiology of sickle cell anaemia and possible treatment. Eur J Haematol. 2019;102(4):319–330. doi:10.1111/ejh.13212
   PubMed Web of Science ®Google Scholar
• Zhang D, Xu C, Manwani D, Frenette PS. Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. Blood. 2016;127(7):801–809. doi:10.1182/blood-2015-09-618538
   PubMed Web of Science ®Google Scholar
• Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010;376(9757):2018–2031. doi:10.1016/S0140-6736(10)61029-X
   PubMed Web of Science ®Google Scholar
• Thein MS, Igbineweka NE, Thein SL. Sickle cell disease in the older adult. Pathology. 2017;49(1):1–9. doi:10.1016/j.pathol.2016.10.002
   PubMed Web of Science ®Google Scholar
• Payne R. Sickle cell anemia and pain: will data prevail over beliefs? Ann Emerg Med. 2009;53(5):596–597. doi:10.1016/j.annemergmed.2008.10.022
   PubMed Web of Science ®Google Scholar
• Shah F, Dwivedi M. Pathophysiology and recent therapeutic insights of sickle cell disease. Ann Hematol. 2020;99(5):925–935. doi:10.1007/s00277-020-03977-9
   PubMed Web of Science ®Google Scholar
• Adebiyi MG, Manalo JM, Xia Y. Metabolomic and molecular insights into sickle cell disease and innovative therapies. Blood Adv. 2019;3(8):1347–1355. doi:10.1182/bloodadvances.2018030619
   PubMed Web of Science ®Google Scholar
• Singh PC, Ballas SK. Emerging drugs for sickle cell anemia. Expert Opin Emerg Drugs. 2015;20(1):47–61. doi:10.1517/14728214.2015.985587
   PubMed Web of Science ®Google Scholar
• Power-Hays A, McGann PT. When actions speak louder than words - racism and sickle cell disease. N Engl J Med. 2020;383:1902–1903. doi:10.1056/NEJMp2022125
   PubMed Web of Science ®Google Scholar
• Bundy DG, Strouse JJ, Casella JF, Miller MR. Urgency of emergency department visits by children with sickle cell disease: a comparison of 3 chronic conditions. Acad Pediatr. 2011;11(4):333–341. doi:10.1016/j.acap.2011.04.006
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Data and statistics: sickle cell disease; 2019. Available from: https://www.cdc.gov/ncbddd/sicklecell/data.html. Accessed November 2, 2020.
   Google Scholar
• National Organization for Rare Disorders. Cystic Fibrosis; 2017. Available from: https://rarediseases.org/rare-diseases/cystic-fibrosis/. Accessed November 2, 2020.
   Google Scholar
• Farooq F, Mogayzel PJ, Lanzkron S, Haywood C, Strouse JJ. Comparison of US federal and foundation funding of research for sickle cell disease and cystic fibrosis and factors associated with research productivity. JAMA Netw Open. 2020;3(3):e201737. doi:10.1001/jamanetworkopen.2020.1737
   PubMed Web of Science ®Google Scholar
• Haywood C, Lanzkron S, Bediako S, et al. Perceived discrimination, patient trust, and adherence to medical recommendations among persons with sickle cell disease. J Gen Intern Med. 2014;29(12):1657–1662. doi:10.1007/s11606-014-2986-7
   PubMed Web of Science ®Google Scholar
• Lee L, Smith-Whitley K, Banks S, Puckrein G. Reducing health care disparities in sickle cell disease: a review. Public Health Rep. 2019;134(6):599–607. doi:10.1177/0033354919881438
   PubMed Web of Science ®Google Scholar
• Pulte D, Lovett PB, Axelrod D, Crawford A, McAna J, Powell R. Comparison of emergency department wait times in adults with sickle cell disease versus other painful etiologies. Hemoglobin. 2016;40(5):330–334. doi:10.1080/03630269.2016.1232272
   PubMed Web of Science ®Google Scholar
• Hsu LL, Green NS, Donnell Ivy E, et al. Community health workers as support for sickle cell care. Am J Prev Med. 2016;51(1 Suppl 1):S87–S98. doi:10.1016/j.amepre.2016.01.016
   PubMed Web of Science ®Google Scholar
• Adams-Graves P, Bronte-Jordan L. Recent treatment guidelines for managing adult patients with sickle cell disease: challenges in access to care, social issues, and adherence. Expert Rev Hematol. 2016;9(6):541–552. doi:10.1080/17474086.2016.1180242
   PubMed Web of Science ®Google Scholar
• Whiteman LN, Lanzkron S, Stewart RW, Haywood C, Strouse JJ, Feldman L. Quality improvement process in a sickle cell infusion center. Am J Med. 2015;128(5):541–544. doi:10.1016/j.amjmed.2014.11.020
   Web of Science ®Google Scholar
• Corvest V, Blais S, Dahmani B, et al. [Cerebral vasculopathy in children with sickle cell disease: key issues and the latest data]. Arch Pediatr. 2018;25(1):63–71. French. doi:10.1016/j.arcped.2017.11.015
   Web of Science ®Google Scholar
• Kassim AA, Galadanci NA, Pruthi S, DeBaun MR. How I treat and manage strokes in sickle cell disease. Blood. 2015;125(22):3401–3410. doi:10.1182/blood-2014-09-551564
   PubMed Web of Science ®Google Scholar
• Adams RJ. TCD in sickle cell disease: an important and useful test. Pediatr Radiol. 2005;35(3):229–234. doi:10.1007/s00247-005-1409-7
   PubMed Web of Science ®Google Scholar
• Medepalli V, Bajaj S, Bajaj M, Badamosi N Recurrent multifocal calvarial bony infarcts and intracranial hematomas in a patient with sickle cell anemia; 2020. Available from: https://www.eurorad.org/case/16842. Accessed November 2, 2020.
   Google Scholar
• Hamm J, Rathore N, Lee P, et al. Cranial epidural hematomas: a case series and literature review of this rare complication associated with sickle cell disease. Pediatr Blood Cancer. 2017;64(3):e26237. doi:10.1002/pbc.26237
   Web of Science ®Google Scholar
• Liem RI, Lanzkron S, Coates T, et al. American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease. Blood Adv. 2019;3(23):3867–3897. doi:10.1182/bloodadvances.2019000916
   PubMed Web of Science ®Google Scholar
• Wyrick-Glatzel J, Conway-Klaassen J. Clinical utility of the IRF: assessment of erythroid regeneration following parvo B19 infection. Clin Lab Sci. 2002;15(4):208–212.
   Google Scholar
• Shah R, Taborda C, Chawla S. Acute and chronic hepatobiliary manifestations of sickle cell disease: a review. World J Gastrointest Pathophysiol. 2017;8(3):108–116. doi:10.4291/wjgp.v8.i3.108
   PubMedGoogle Scholar
• Anele UA, Le BV, Resar LMS, Burnett AL. How I treat priapism. Blood. 2015;125(23):3551–3558. doi:10.1182/blood-2014-09-551887
   PubMed Web of Science ®Google Scholar
• Martí‐Carvajal AJ, Solà I, Agreda‐Pérez LH. Treatment for avascular necrosis of bone in people with sickle cell disease. Cochrane Database Syst Rev. 2016;8.
   Web of Science ®Google Scholar
• Lebensburger JD, Bemrich-Stolz CJ, Howard TH. Barriers in transition from pediatrics to adult medicine in sickle cell anemia. J Blood Med. 2012;3:105–112. doi:10.2147/JBM.S32588
   Google Scholar
• Ogu UO, Billett HH. Comorbidities in sickle cell disease: adult providers needed! Indian J Med Res. 2018;147(6):527–529. doi:10.4103/ijmr.IJMR_1019_18
   Web of Science ®Google Scholar
• Jain S, Bakshi N, Krishnamurti L. Acute chest syndrome in children with sickle cell disease. Pediatr Allergy Immunol Pulmonol. 2017;30(4):191–201. doi:10.1089/ped.2017.0814
   PubMed Web of Science ®Google Scholar
• Ballas SK, Lieff S, Benjamin LJ, et al. Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol. 2010;85(1):6–13. doi:10.1002/ajh.21550
   PubMed Web of Science ®Google Scholar
• Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. N Engl J Med. 2000;342(25):1855–1865. doi:10.1056/NEJM200006223422502
   PubMed Web of Science ®Google Scholar
• Dampier C, Palermo TM, Darbari DS, Hassell K, Smith W, Zempsky W. AAPT diagnostic criteria for chronic sickle cell disease pain. J Pain. 2017;18(5):490–498. doi:10.1016/j.jpain.2016.12.016
   PubMed Web of Science ®Google Scholar
• Edwards LY, Edwards CL. Psychosocial treatments in pain management of sickle cell disease. J Natl Med Assoc. 2010;102(11):1084–1094. doi:10.1016/S0027-9684(15)30737-9
   PubMed Web of Science ®Google Scholar
• Williams H, Tanabe P. Sickle cell disease: a review of nonpharmacological approaches for pain. J Pain Symptom Manage. 2016;51(2):163–177. doi:10.1016/j.jpainsymman.2015.10.017
   PubMed Web of Science ®Google Scholar
• Shet AS, Wun T. How I diagnose and treat venous thromboembolism in sickle cell disease. Blood. 2018;132(17):1761–1769. doi:10.1182/blood-2018-03-822593
   Web of Science ®Google Scholar
• Olatunya OS, Albuquerque DM, Adekile AD, Costa FF. Evaluation of sociodemographic, clinical, and laboratory markers of sickle leg ulcers among young Nigerians at a tertiary health institution. Niger J Clin Pract. 2018;21(7):882–887. doi:10.4103/njcp.njcp_4_18
   PubMed Web of Science ®Google Scholar
• Serjeant GR, Serjeant BE, Mohan JS, Clare A. Leg ulceration in sickle cell disease: medieval medicine in a modern world. Hematol Oncol Clin North Am. 2005;19(5):943–ix. doi:10.1016/j.hoc.2005.08.005
   PubMed Web of Science ®Google Scholar
• Minniti CP, Kato GJ. Critical reviews: how we treat sickle cell patients with leg ulcers. Am J Hematol. 2016;91(1):22–30. doi:10.1002/ajh.24134
   Web of Science ®Google Scholar
• Vasconcelos A, Prior AR, Ferrão A, Morais A. An adolescent with sickle cell anaemia experiencing disease-related complications: priapism and leg ulcer–a management challenge. BMJ Case Rep. 2012;2012:bcr1120115146–bcr1120115146. doi:10.1136/bcr.11.2011.5146
   Google Scholar
• Smith-Whitley K. Reproductive issues in sickle cell disease. Blood. 2014;124(24):3538–3543. doi:10.1182/blood-2014-07-577619
   PubMed Web of Science ®Google Scholar
• Taddesse A, Woldie IL, Khana P, et al. Hypogonadism in patients with sickle cell disease: central or peripheral? Acta Haematol. 2012;128(2):65–68. doi:10.1159/000337344
   Web of Science ®Google Scholar
• Madu AJ, Ubesie A, Ocheni S, et al. Priapism in homozygous sickle cell patients: important clinical and laboratory associations. Med Princ Pract. 2014;23(3):259–263. doi:10.1159/000360608
   PubMed Web of Science ®Google Scholar
• Serjeant GR, Singhal A, Hambleton IR. Sickle cell disease and age at menarche in Jamaican girls: observations from a cohort study. Arch Dis Child. 2001;85(5):375–378. doi:10.1136/adc.85.5.375
   PubMed Web of Science ®Google Scholar
• Smith-Whitley K. Complications in pregnant women with sickle cell disease. Hematology Am Soc Hematol Educ Program. 2019;2019(1):359–366. doi:10.1182/hematology.2019000039
   PubMed Web of Science ®Google Scholar
• Nnoli A, Seligman NS, Dysart K, Baxter JK, Ballas SK. Opioid utilization by pregnant women with sickle cell disease and the risk of neonatal abstinence syndrome. J Natl Med Assoc. 2018;110(2):163–168. doi:10.1016/j.jnma.2017.04.002
   PubMed Web of Science ®Google Scholar
• Johns Hopkins University & Medicine. COVID-19 map; 2020. Available from: https://coronavirus.jhu.edu/map.html. Accessed November 2, 2020.
   Google Scholar
• Sickle Cell Society. Coronavirus (COVID-19) & sickle cell disorder; 2020. Available from: https://www.sicklecellsociety.org/coronavirus-and-scd/. Accessed November 2, 2020.
   Google Scholar
• Medical College of Wisconsin. SECURE-SCD registry; 2020. Available from: https://covidsicklecell.org/updates-data/. Accessed November 2, 2020.
   Google Scholar
• Arlet JB, de Luna G, Khimoud D, et al. Prognosis of patients with sickle cell disease and COVID-19: a French experience. Lancet Haematol. 2020;7(9):e632–e634. doi:10.1016/S2352-3026(20)30204-0
   PubMed Web of Science ®Google Scholar
• Hussain FA, Njoku FU, Saraf SL, Molokie RE, Gordeuk VR, Han J. COVID-19 infection in patients with sickle cell disease. Br J Haematol. 2020;189(5):851–852. doi:10.1111/bjh.16734
   PubMed Web of Science ®Google Scholar
• Sahu KK, Siddiqui AD, Cerny J. Managing sickle cell patients with COVID-19 infection: the need to pool our collective experience. Br J Haematol. 2020;190(2):e86–e89. doi:10.1111/bjh.16880
   PubMed Web of Science ®Google Scholar
• American Society of Hematology. COVID-19; 2020. Available from: https://www.hematology.org/covid-19. Accessed November 2, 2020.
   Google Scholar
• Baker JP. Sickle Cell Anemia. Trans Am Clin Climatol Assoc. 1941;57:203–212.
   Google Scholar
• Howard J. Sickle cell disease: when and how to transfuse. Hematology Am Soc Hematol Educ Program. 2016;2016(1):625–631. doi:10.1182/asheducation-2016.1.625
   PubMed Web of Science ®Google Scholar
• Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339(1):5–11. doi:10.1056/NEJM199807023390102
   PubMed Web of Science ®Google Scholar
• Adams RJ, Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005;353(26):2769–2778.
   PubMed Web of Science ®Google Scholar
• Ware RE, Helms RW. Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood. 2012;119(17):3925–3932. doi:10.1182/blood-2011-11-392340
   PubMed Web of Science ®Google Scholar
• DeBaun MR, Gordon M, McKinstry RC, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014;371(8):699–710. doi:10.1056/NEJMoa1401731
   PubMed Web of Science ®Google Scholar
• Ware RE, Davis BR, Schultz WH, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, Phase 3, non-inferiority trial. Lancet. 2016;387(10019):661–670. doi:10.1016/S0140-6736(15)01041-7
   PubMed Web of Science ®Google Scholar
• Howard J, Malfroy M, Llewelyn C, et al. The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial. Lancet. 2013;381(9870):930–938. doi:10.1016/S0140-6736(12)61726-7
   PubMed Web of Science ®Google Scholar
• Koshy M, Burd L, Wallace D, Moawad A, Baron J. Prophylactic red-cell transfusions in pregnant patients with sickle cell disease. A randomized cooperative study. N Engl J Med. 1988;319(22):1447–1452. doi:10.1056/NEJM198812013192204
   PubMed Web of Science ®Google Scholar
• Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med. 1995;332(20):1317–1322. doi:10.1056/NEJM199505183322001
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA approves hydroxyurea for treatment of pediatric patients with sickle cell anemia; 2020. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-hydroxyurea-treatment-pediatric-patients-sickle-cell-anemia. Accessed October 18, 2020.
   Google Scholar
• McGann PT, Ware RE. Hydroxyurea therapy for sickle cell anemia. Expert Opin Drug Saf. 2015;14(11):1749–1758. doi:10.1517/14740338.2015.1088827
   PubMed Web of Science ®Google Scholar
• Verma HK, Lakkakula S, Lakkakula BVKS. Retrospection of the effect of hydroxyurea treatment in patients with sickle cell disease. Acta Haematol Pol. 2018;49(1):1. doi:10.2478/ahp-2018-0001
   Google Scholar
• Niihara Y, Miller ST, Kanter J, et al. A phase 3 trial of l-glutamine in sickle cell disease. N Engl J Med. 2018;379(3):226–235. doi:10.1056/NEJMoa1715971
   PubMed Web of Science ®Google Scholar
• Ogu UO, Thomas M, Chan F, et al. L-glutamine use in adults with sickle cell disease: clinical trials where success meets reality. Am J Hematol. 2020.
   Web of Science ®Google Scholar
• Matsui NM, Borsig L, Rosen SD, Yaghmai M, Varki A, Embury SH. P-selectin mediates the adhesion of sickle erythrocytes to the endothelium. Blood. 2001;98(6):1955–1962. doi:10.1182/blood.V98.6.1955
   PubMed Web of Science ®Google Scholar
• Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376(5):429–439. doi:10.1056/NEJMoa1611770
   PubMed Web of Science ®Google Scholar
• Oksenberg D, Dufu K, Patel MP, et al. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease. Br J Haematol. 2016;175(1):141–153. doi:10.1111/bjh.14214
   PubMed Web of Science ®Google Scholar
• Vichinsky E, Hoppe CC, Ataga KI, et al. A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med. 2019;381(6):509–519. doi:10.1056/NEJMoa1903212
   PubMed Web of Science ®Google Scholar
• Johnson FL, Look AT, Gockerman J, Ruggiero MR, Dalla-Pozza L, Billings FT. Bone-marrow transplantation in a patient with sickle-cell anemia. N Engl J Med. 1984;311(12):780–783. doi:10.1056/NEJM198409203111207
   PubMed Web of Science ®Google Scholar
• Vermylen C, Fernandez Robles E, Ninane J, Cornu G. Bone marrow transplantation in five children with sickle cell anaemia. Lancet. 1988;331(8600):1427–1428. doi:10.1016/S0140-6736(88)92239-8
   Google Scholar
• Ferster A, De Valck C, Azzi N, Fondu P, Toppet M, Sariban E. Bone marrow transplantation for severe sickle cell anaemia. Br J Haematol. 1992;80(1):102–105. doi:10.1111/j.1365-2141.1992.tb06407.x
   PubMed Web of Science ®Google Scholar
• Vermylen C, Cornu G. Bone marrow transplantation for sickle cell disease. The European experience. Am J Pediatr Hematol Oncol. 1994;16(1):18–21.
   PubMedGoogle Scholar
• Johnson FL, Mentzer WC, Kalinyak KA, Sullivan KM, Abboud MR. Bone marrow transplantation for sickle cell disease. The United States experience. Am J Pediatr Hematol Oncol. 1994;16(1):22–26.
   Google Scholar
• Walters MC, Patience M, Leisenring W, et al. Bone marrow transplantation for sickle cell disease. N Engl J Med. 1996;335(6):369–376. doi:10.1056/NEJM199608083350601
   PubMed Web of Science ®Google Scholar
• Walters MC, De Castro LM, Sullivan KM, et al. Indications and results of HLA-identical sibling hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2016;22(2):207–211. doi:10.1016/j.bbmt.2015.10.017
   PubMed Web of Science ®Google Scholar
• Gluckman E, Cappelli B, Bernaudin F, et al. Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood. 2017;129(11):1548–1556. doi:10.1182/blood-2016-10-745711
   PubMed Web of Science ®Google Scholar
• Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. Nat Rev Dis Primers. 2018;4:18010.
   PubMed Web of Science ®Google Scholar
• Demirci S, Uchida N, Tisdale JF. Gene therapy for sickle cell disease: an update. Cytotherapy. 2018;20(7):899–910. doi:10.1016/j.jcyt.2018.04.003
   PubMed Web of Science ®Google Scholar
• Ribeil JA, Hacein-Bey-Abina S, Payen E, et al. Gene therapy in a patient with sickle cell disease. N Engl J Med. 2017;376(9):848–855. doi:10.1056/NEJMoa1609677
   PubMed Web of Science ®Google Scholar
• Magrin E, Semeraro M, Magnani A, et al. Results from the Completed Hgb-205 Trial of Lentiglobin for Β-Thalassemia and Lentiglobin for Sickle Cell Disease Gene Therapy. Washington, DC: American Society of Hematology; 2019.
   Google Scholar
• Kanter J, Tisdale JF, Mapara MY, et al. Resolution of Sickle Cell Disease Manifestations in Patients Treated with Lentiglobin Gene Therapy: Updated Results from the Phase 1/2 Hgb-206 Group C Study. Washington, DC: American Society of Hematology; 2019.
   Google Scholar
• Rai P, Ataga KI. Drug Therapies for the Management of Sickle Cell Disease. F1000Res. 2020; 9.
   Google Scholar